This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexander, H. R. Articles by Beresneva, T. Search for Related Content PubMed PubMed Citation Articles by Alexander, H. R., Jr. Articles by Beresneva, T.

Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver

¹ Surgical Metabolism Section, Surgery Branch, Center for Cancer Research and
² Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

ABSTRACT

Purpose: Liver metastases are the sole or life-limiting component of disease in the majority of patients with ocular melanoma who recur. Because median survival after diagnosis of liver metastases is short and no satisfactory treatment options exist, we have conducted clinical trials evaluating isolated hepatic perfusion (IHP) for patients afflicted with this condition.

Experimental Design: Twenty-nine patients (male: 14, female: 15; mean age, 49 years) with unresectable liver metastases from ocular melanoma were treated with a 60-min hyperthermic IHP using 1.5 mg/kg of melphalan (mean total dose 105 mg). Via laparotomy, perfusion inflow was established with a cannula in the gastroduodenal artery and outflow via a cannula positioned in an isolated segment of the retrohepatic inferior vena cava. Portal and infra-renal inferior vena cava blood flow was shunted externally to the axillary vein using a veno-veno bypass circuit. Patients were assessed for toxicity, radiographic response, and survival.

Results: There was no treatment related mortality and transient grade 3/4 hepatic toxicity was observed in 19 patients (65%). Mean length of operation and hospital stay was 8.3 h and 10 days, respectively. There were 3 (10%) complete responses (duration: 12, 14+, 15 months) and 15 partial responses (52%; mean duration: 10 months). The initial site of disease progression included liver in 17 of 25 patients (68%) who recurred. At a median follow-up of 30.7 months the median actuarial progression-free and overall survivals were 8 and 12.1 months, respectively.

Conclusions: IHP with melphalan alone results in significant regression of established liver metastases for patients with ocular melanoma. However, after IHP, disease progression is most commonly observed in the liver, and survival after disease progression is short. On the basis of a pattern of tumor progression predominantly in liver, continued clinical evaluation of hepatic directed therapy in this patient population is justified.

This article has been cited by other articles:

				L. B. J. van Iersel, E. J. Hoekman, H. Gelderblom, A. L. Vahrmeijer, E. L. van Persijn van Meerten, F. G. J. Tijl, H. H. Hartgrink, P. J. K. Kuppen, J. W. R. Nortier, R. A. E. M. Tollenaar, et al. Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases Ann. Surg. Oncol., July 1, 2008; 15(7): 1891 - 1898. [Abstract] [Full Text] [PDF]

				C. Verhoef, J. H. W. deWilt, F. Brunstein, A. W. K. S. Marinelli, B. vanEtten, M. Vermaas, G. Guetens, G. de Boeck, E. A. de Bruijn, and A. M. M. Eggermont Isolated Hypoxic Hepatic Perfusion with Retrograde Outflow in Patients with Irresectable Liver Metastases; A New Simplified Technique in Isolated Hepatic Perfusion Ann. Surg. Oncol., May 1, 2008; 15(5): 1367 - 1374. [Abstract] [Full Text] [PDF]

				S. Mocellin, P. Pilati, P. Da Pian, M. Forlin, S. Corazzina, C. R. Rossi, F. Innocente, C. Ori, D. Casara, F. Ujka, et al. Correlation Between Melphalan Pharmacokinetics and Hepatic Toxicity Following Hyperthermic Isolated Liver Perfusion for Unresectable Metastatic Disease Ann. Surg. Oncol., February 1, 2007; 14(2): 802 - 809. [Abstract] [Full Text] [PDF]

				E. S. Gragoudas Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4666 - 4673. [Full Text] [PDF]

				P. Rietschel, K. S. Panageas, C. Hanlon, A. Patel, D. H. Abramson, and P. B. Chapman Variates of Survival in Metastatic Uveal Melanoma J. Clin. Oncol., November 1, 2005; 23(31): 8076 - 8080. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr. A Motion for Cautious Optimism in the Treatment of Patients With Ocular Melanoma: The Ayes Have It Ann. Surg. Oncol., June 1, 2005; 12(6): 417 - 419. [Full Text] [PDF]

				H. R. Alexander Jr., S. K. Libutti, J. F. Pingpank, D. L. Bartlett, C. Helsabeck, and T. Beresneva Isolated Hepatic Perfusion for the Treatment of Patients With Colorectal Cancer Liver Metastases After Irinotecan-Based Therapy Ann. Surg. Oncol., February 1, 2005; 12(2): 138 - 144. [Abstract] [Full Text] [PDF]

				A. Grover and H. R. Alexander Jr. The Past Decade of Experience With Isolated Hepatic Perfusion Oncologist, November 1, 2004; 9(6): 653 - 664. [Abstract] [Full Text] [PDF]

				B. van Etten, F. Brunstein, M. G. A. van IJken, A. W. K. S. Marinelli, C. Verhoef, J. R. M. van der Sijp, G. Guetens, G. de Boeck, E. A. de Bruijn, J. H. W. de Wilt, et al. Isolated Hypoxic Hepatic Perfusion With Orthograde or Retrograde Flow in Patients With Irresectable Liver Metastases Using Percutaneous Balloon Catheter Techniques: A Phase I and II Study Ann. Surg. Oncol., June 1, 2004; 11(6): 598 - 605. [Abstract] [Full Text] [PDF]

				E. D. Feldman, J. F. Pingpank, and H. R. Alexander Jr. Regional Treatment Options for Patients With Ocular Melanoma Metastatic to the Liver Ann. Surg. Oncol., March 1, 2004; 11(3): 290 - 297. [Abstract] [Full Text] [PDF]